{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:56:09Z","timestamp":1793346969513,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jsat.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T11:34:45Z","timestamp":1563536085000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders"],"prefix":"10.1016","volume":"108","author":[{"given":"Sharon","family":"Reif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Brolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen T.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Speaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna B.","family":"Mazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.15288\/jsad.2013.74.258","article-title":"Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States","volume":"74","author":"Abraham","year":"2013","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.007_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.07.007_bb0015","author":"American Society of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.007_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: Development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.07.007_bb0025","unstructured":"Centers for Disease Control and Prevention. (n.d.). Opioid overdose: Understanding the epidemic. Retrieved from: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html\" id=\"ir0010\">https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html. Accessed 30 January 2019."},{"key":"10.1016\/j.jsat.2019.07.007_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsat.2017.02.011","article-title":"The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015)","volume":"85","author":"Cousins","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.07.007_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.161.2.248","article-title":"Screening and intervention for illicit drug abuse: A national survey of primary care physicians and psychiatrists","volume":"161","author":"Friedmann","year":"2001","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: Assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2019.07.007_bb0045","author":"Gerrity"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Annals of Family Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2019.07.007_bb0055","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.007_bb0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","article-title":"Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure","volume":"34","author":"Knudsen","year":"2011","journal-title":"Evaluation and Program Planning"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.007_bb0065","doi-asserted-by":"crossref","first-page":"476","DOI":"10.15288\/jsad.2014.75.476","article-title":"The transition to medication adoption in publicly funded substance use disorder treatment programs: Organizational structure, culture, and resources","volume":"75","author":"Knudsen","year":"2014","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.007_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care-based models for the treatment of opioid use disorder: A scoping review","volume":"166","author":"Korthuis","year":"2017","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.07.007_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the Massachusetts Collaborative Care Model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.jsat.2019.07.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: What actually works? A systematic review","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"issue":"10118","key":"10.1016\/j.jsat.2019.07.007_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2019.07.007_bb0090","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev-publhealth-040617-013526","article-title":"Treatment and prevention of opioid use disorder: Challenges and opportunities","volume":"39","author":"McCarty","year":"2018","journal-title":"Annual Review of Public Health"},{"key":"10.1016\/j.jsat.2019.07.007_bb0095","doi-asserted-by":"crossref","unstructured":"Murphy, S. M., McCollister, K. E., Leff, J. A., Yang, X., Jeng, P. J., Lee, J. D., \u2026 Schackman, B. R. (2018). Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Annals of Internal Medicine.","DOI":"10.7326\/M18-0227"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.007_bb0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome them","volume":"13","author":"Oliva","year":"2011","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.jsat.2019.07.007_bb0105","author":"Rawson"},{"key":"10.1016\/j.jsat.2019.07.007_bb0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/02791072.2017.1300360","article-title":"Commercial health plan coverage of selected treatments for opioid use disorders from 2003 to 2014","volume":"49","author":"Reif","year":"2017","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2019.07.007_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsat.2016.03.001","article-title":"Access to addiction pharmacotherapy in private health plans","volume":"66","author":"Reif","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.007_bb0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.007_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1804059","article-title":"Moving addiction care to the mainstream - Improving the quality of buprenorphine treatment","volume":"379","author":"Saloner","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2019.07.007_bb0135","author":"SAMHSA"},{"key":"10.1016\/j.jsat.2019.07.007_bb0140","author":"SAMHSA"},{"issue":"6","key":"10.1016\/j.jsat.2019.07.007_bb0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.007_bb0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The untapped potential of office-based buprenorphine treatment","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2019.07.007_bb0155","series-title":"Washington state targeted response to opioid crisis: Hub and spoke monthly summary report, July 2017 \u2013 December 2018","author":"Speaker","year":"2019"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.07.007_bb0160","doi-asserted-by":"crossref","first-page":"A63","DOI":"10.1186\/1940-0640-10-S1-A63","article-title":"A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based burprenorphine providers","volume":"10","author":"Stoller","year":"2015","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2019.07.007_bb0165","author":"Stoller"},{"key":"10.1016\/j.jsat.2019.07.007_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2019.07.007_bb0180","author":"U.S. Surgeon General"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: A review","volume":"76","author":"Volkow","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.007_bb0190","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","article-title":"Barriers to medications for addiction treatment: How stigma kills","volume":"53","author":"Wakeman","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2019.07.007_bb0195","series-title":"Washington Opioid State Targeted Response Project (WA-Opioid STR), application in response to SAMHSA FOA-TI-17-014","author":"Washington State","year":"2017"},{"key":"10.1016\/j.jsat.2019.07.007_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.07.007_bb0205","first-page":"1","article-title":"Development of a cascade of care for responding to the opioid epidemic","author":"Williams","year":"2019","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2019.07.007_bb0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2015.07.011","article-title":"Local implementation of alcohol screening and brief intervention at five Veterans Health Administration primary care clinics: Perspectives of clinical and administrative staff","volume":"60","author":"Williams","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.jsat.2019.07.007_bb0215","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/appi.ajp.2012.11111616","article-title":"Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: Systematic review and meta-analysis","volume":"169","author":"Woltmann","year":"2012","journal-title":"American Journal of Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219300637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219300637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:31Z","timestamp":1760039431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219300637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"alternative-id":["S0740547219300637"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.07.007","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}